Distinct clinical-immunological subtypes define prognostic heterogeneity in anti-U1RNP-positive connective tissue diseases.
Liu Di D, Zhang Jingyi J, Zhang Jing J, Hu Nan N et al.
Anti-U1 ribonucleoprotein (U1RNP) antibody-positive connective tissue diseases (CTDs) exhibit marked clinical heterogeneity that is not adequately captured by conventional diagnostic classifications. This study aimed to identify intrinsic clinical-immunological subtypes and assess their prognostic implications. In this single-center retrospective cohort, 358 patients with anti-U1RNP-positive CTDs were analyzed using multiple correspondence analysis and hierarchical clustering. Key discriminative features were identified through least absolute shrinkage and selection operator (LASSO) regression. Peripheral blood lymphocyte subsets were assessed by flow cytometry, and long-term survival was compared using Kaplan-Meier analysis. Clustering analysis identified three clinical-immunological subtypes with significant differences. Cluster 1, the "mild immunological type", was characterized by minimal autoantibody positivity and relatively normal lymphocyte counts, and exhibited the most favorable prognosis. Cluster 2, the "exocrine gland-joint-muscle involvement type", presented with prominent sicca symptoms, arthralgia, elevated creatine kinase (CK), and interstitial lung disease (ILD), and had an intermediate prognosis. Cluster 3, the "severe systemic type", was associated with marked pericarditis, renal injury, multiple autoantibody positivity, and widespread lymphopenia, and had the poorest survival. LASSO analysis highlighted normal T lymphocyte and T follicular helper cell counts for cluster 1, elevated CK and rheumatoid factor for cluster 2, and anti-dsDNA/anti-nucleosome antibodies, elevated D-dimer, and major organ involvement for cluster 3. Anti-U1RNP-positive CTDs comprise distinct clinical-immunological subtypes with different clinical features, immune profiles, and prognostic outcomes. Subtype-based stratification may facilitate precision management, particularly for patients with multiple autoantibody positivity and severe lymphopenia who are at high risk of poor prognosis.